Limits...
Chronic treatment with a carbon monoxide releasing molecule reverses dietary induced obesity in mice.

Hosick PA, AlAmodi AA, Hankins MW, Stec DE - Adipocyte (2015)

Bottom Line: Chronic treatment with CORM-A1 resulted in a 33% decrease from initial body weight over the 30 week treatment period while treatment with iCORM and saline were associated with 18 and 25% gain in initial body weight over the same time frame.Chronic treatment with CORM-A1 did not affect food intake or activity but resulted in a significant increase in metabolism.CORM-A1 treatment also resulted in lower fasting blood glucose, improvement in insulin sensitivity and decreased heptatic steatosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Physiology & Biophysics; Center for Excellence in Cardiovascular-Renal Research; University of Mississippi Medical Center; Jackson, MS USA; Department of Exercise Science and Physical Education; Montclair State University; Montclair, NJ USA.

ABSTRACT
Chronic, low level treatment with a carbon monoxide releasing molecule (CO-RM), CORM-A1, has been shown to prevent the development of obesity in response to a high fat diet. The objective of this study was to test the hypothesis that chronic, low level treatment with this CO-RM can reverse established obesity via a mechanism independent of food intake. Dietary induced obese mice were treated with CORM-A1, the inactive compound iCORM-A1, or saline every 48 hours for 30 weeks while maintained on a high fat (60%) diet. Chronic treatment with CORM-A1 resulted in a 33% decrease from initial body weight over the 30 week treatment period while treatment with iCORM and saline were associated with 18 and 25% gain in initial body weight over the same time frame. Chronic treatment with CORM-A1 did not affect food intake or activity but resulted in a significant increase in metabolism. CORM-A1 treatment also resulted in lower fasting blood glucose, improvement in insulin sensitivity and decreased heptatic steatosis. Chronic treatment with CO releasing molecules can reverse dietary induced obesity and normalize insulin resistance independent of changes in food intake or activity. These findings are likely though a mechanism which increases metabolism.

No MeSH data available.


Related in: MedlinePlus

(A) Measurement of fasting blood glucose in experimental groups. Fasting blood glucose was measured at baseline and every 6 weeks for entire 30 week treatment. (B) fasting plasma insulin levels measured at baseline, 24 and 30 weeks of treatment. * = P < 0.05 as compared to other groups. † = P < 0.05 as compared to time 0 value.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836479&req=5

f0003: (A) Measurement of fasting blood glucose in experimental groups. Fasting blood glucose was measured at baseline and every 6 weeks for entire 30 week treatment. (B) fasting plasma insulin levels measured at baseline, 24 and 30 weeks of treatment. * = P < 0.05 as compared to other groups. † = P < 0.05 as compared to time 0 value.

Mentions: Fasting blood glucose levels were elevated above normal to similar levels in all groups prior to treatment. CORM-A1 treatment resulted in significant attenuation of hyperglycemia starting at 6 weeks of treatment and lasting throughout the duration of the study (Fig. 3A). At 30 weeks of treatment fasting blood glucose levels in CORM-A1 treated mice were 55% of those observed in control mice (Fig. 3A). Fasting plasma insulin levels were also elevated to a similar degree in all groups prior to treatment. CORM-A1 treatment resulted in a significant decrease in plasma insulin levels as compared to all other groups at both 24 and 30 weeks of treatment (Fig. 3B). CORM-A1 treatment also significantly decreased plasma insulin levels from time 0 values (Fig. 3B).Figure 3.


Chronic treatment with a carbon monoxide releasing molecule reverses dietary induced obesity in mice.

Hosick PA, AlAmodi AA, Hankins MW, Stec DE - Adipocyte (2015)

(A) Measurement of fasting blood glucose in experimental groups. Fasting blood glucose was measured at baseline and every 6 weeks for entire 30 week treatment. (B) fasting plasma insulin levels measured at baseline, 24 and 30 weeks of treatment. * = P < 0.05 as compared to other groups. † = P < 0.05 as compared to time 0 value.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836479&req=5

f0003: (A) Measurement of fasting blood glucose in experimental groups. Fasting blood glucose was measured at baseline and every 6 weeks for entire 30 week treatment. (B) fasting plasma insulin levels measured at baseline, 24 and 30 weeks of treatment. * = P < 0.05 as compared to other groups. † = P < 0.05 as compared to time 0 value.
Mentions: Fasting blood glucose levels were elevated above normal to similar levels in all groups prior to treatment. CORM-A1 treatment resulted in significant attenuation of hyperglycemia starting at 6 weeks of treatment and lasting throughout the duration of the study (Fig. 3A). At 30 weeks of treatment fasting blood glucose levels in CORM-A1 treated mice were 55% of those observed in control mice (Fig. 3A). Fasting plasma insulin levels were also elevated to a similar degree in all groups prior to treatment. CORM-A1 treatment resulted in a significant decrease in plasma insulin levels as compared to all other groups at both 24 and 30 weeks of treatment (Fig. 3B). CORM-A1 treatment also significantly decreased plasma insulin levels from time 0 values (Fig. 3B).Figure 3.

Bottom Line: Chronic treatment with CORM-A1 resulted in a 33% decrease from initial body weight over the 30 week treatment period while treatment with iCORM and saline were associated with 18 and 25% gain in initial body weight over the same time frame.Chronic treatment with CORM-A1 did not affect food intake or activity but resulted in a significant increase in metabolism.CORM-A1 treatment also resulted in lower fasting blood glucose, improvement in insulin sensitivity and decreased heptatic steatosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Physiology & Biophysics; Center for Excellence in Cardiovascular-Renal Research; University of Mississippi Medical Center; Jackson, MS USA; Department of Exercise Science and Physical Education; Montclair State University; Montclair, NJ USA.

ABSTRACT
Chronic, low level treatment with a carbon monoxide releasing molecule (CO-RM), CORM-A1, has been shown to prevent the development of obesity in response to a high fat diet. The objective of this study was to test the hypothesis that chronic, low level treatment with this CO-RM can reverse established obesity via a mechanism independent of food intake. Dietary induced obese mice were treated with CORM-A1, the inactive compound iCORM-A1, or saline every 48 hours for 30 weeks while maintained on a high fat (60%) diet. Chronic treatment with CORM-A1 resulted in a 33% decrease from initial body weight over the 30 week treatment period while treatment with iCORM and saline were associated with 18 and 25% gain in initial body weight over the same time frame. Chronic treatment with CORM-A1 did not affect food intake or activity but resulted in a significant increase in metabolism. CORM-A1 treatment also resulted in lower fasting blood glucose, improvement in insulin sensitivity and decreased heptatic steatosis. Chronic treatment with CO releasing molecules can reverse dietary induced obesity and normalize insulin resistance independent of changes in food intake or activity. These findings are likely though a mechanism which increases metabolism.

No MeSH data available.


Related in: MedlinePlus